Sanara MedTech (SMTI) Cantor Global Healthcare Conference 2025 summary

Leadership and organizational development

• Newly appointed CEO brings eight years of experience across multiple leadership roles, with a formal transition to CEO effective September 15, 2025.

• CFO joined in January, attracted by the company's culture and growth prospects, and brings extensive finance and wound care experience.

• Leadership team has expanded significantly in recent years, positioning the company for future scaling.

Business evolution and growth drivers

• Transitioned from a single-product company to a diversified portfolio including soft tissue and bone fusion products.

• Achieved strong Q2 results with $25.8 million in revenue, driven by balanced growth in both core product lines.

• Scendia acquisition in 2023 contributed to a 25% increase in bone fusion product sales.

• Operating leverage achieved by optimizing the sales force and building out senior management, resulting in positive cash flow and steady margins.

Market expansion and sales strategy

• Core business remains in spine and orthopedics, but expansion into foot, ankle, plastics, and vascular specialties is underway.

• Over 400 distributor contracts in place, with ongoing efforts to deepen penetration across contracted facilities and surgeon base.

• Sales growth strategy focuses on distributor performance, facility approvals, and surgeon engagement.